Bethany Fitzsimmons
Overview
Explore the profile of Bethany Fitzsimmons including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
561
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lister K, Wong C, Uttam S, Parisien M, Stecum P, Brown N, et al.
bioRxiv
. 2024 Jul;
PMID: 38979173
Sensitization of spinal nociceptive circuits plays a crucial role in neuropathic pain. This sensitization depends on new gene expression that is primarily regulated via transcriptional and translational control mechanisms. The...
2.
Mummery C, Borjesson-Hanson A, Blackburn D, Vijverberg E, De Deyn P, Ducharme S, et al.
Nat Med
. 2023 Oct;
30(1):304.
PMID: 37845513
No abstract available.
3.
Donohue K, Fitzsimmons B, Bruntz R, Markussen K, Young L, Clarke H, et al.
Neurotherapeutics
. 2023 Sep;
20(6):1808-1819.
PMID: 37700152
Patients with Lafora disease have a mutation in EPM2A or EPM2B, resulting in dysregulation of glycogen metabolism throughout the body and aberrant glycogen molecules that aggregate into Lafora bodies. Lafora...
4.
Mummery C, Borjesson-Hanson A, Blackburn D, Vijverberg E, De Deyn P, Ducharme S, et al.
Nat Med
. 2023 Apr;
29(6):1437-1447.
PMID: 37095250
Tau plays a key role in Alzheimer's disease (AD) pathophysiology, and accumulating evidence suggests that lowering tau may reduce this pathology. We sought to inhibit MAPT expression with a tau-targeting...
5.
Sullivan J, Mazur C, Wolf D, Horky L, Currier N, Fitzsimmons B, et al.
J Transl Med
. 2020 Aug;
18(1):309.
PMID: 32771027
Background: The intrathecal (IT) dosing route introduces drugs directly into the CSF to bypass the blood-brain barrier and gain direct access to the CNS. We evaluated the use of convective...
6.
Luo X, Fitzsimmons B, Mohan A, Zhang L, Terrando N, Kordasiewicz H, et al.
Brain Behav Immun
. 2017 Nov;
72:34-44.
PMID: 29128611
p38 mitogen-activated protein kinase (MAPK) consists of two major isoforms: p38α and p38β; however, it remains unclear which isoform is more important for chronic pain development. Recently, we developed potent,...
7.
Mohan A, Fitzsimmons B, Zhao H, Jiang Y, Mazur C, Swayze E, et al.
Pain
. 2017 Oct;
159(1):139-149.
PMID: 28976422
There is an urgent need for better treatments for chronic pain, which affects more than 1 billion people worldwide. Antisense oligonucleotides (ASOs) have proven successful in treating children with spinal...
8.
Mazur C, Fitzsimmons B, Kamme F, Nichols B, Powers B, Wancewicz E
J Neurosci Methods
. 2017 Feb;
280:36-46.
PMID: 28163066
Background: The blood brain barrier (BBB) is an impediment to the development of large and highly charged molecules as therapeutics for diseases and injuries of the central nervous system (CNS)....
9.
Svensson E, Persson J, Fitzsimmons B, Yaksh T
Neurosci Lett
. 2013 May;
548:27-32.
PMID: 23707652
Neurosteroids regulate neuronal excitability though binding sites associated with the ionotropic γ-aminobutyric acid (GABAA) receptor. We sought to characterize the spinal analgesic actions in rats of two 5α-reduced neurosteroids, allopregnanolone...
10.
Wahlert A, Funkelstein L, Fitzsimmons B, Yaksh T, Hook V
Neuropeptides
. 2013 Jan;
47(2):109-15.
PMID: 23290538
Dynorphin peptide neurotransmitters (neuropeptides) have been implicated in spinal pain processing based on the observations that intrathecal delivery of dynorphin results in proalgesic effects and disruption of extracellular dynorphin activity...